Clinical trials: ctDNA Monitoring
Lymphoma, Lymphoma, B-Cell
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd…
- Trial name
- NCT06954805
- Testing
- Rituximab, Etoposide, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Jennifer Amengual
Hepatocellular Carcinoma Resectable, Surgery
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy.
- Conditions
- Hepatocellular Carcinoma Resectable, Surgery, Recurrence
- Trial name
- NCT06449846
- Testing
- circulating tumor cell DNA detection
- Where
- 4 sites in China
- Volunteers
- 152 people
- Sponsor
- Zhujiang Hospital
Gastric Cancer Stage III
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with…
- Trial name
- NCT06939439
- Testing
- Tislelizumab + SOX Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 416 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma (ESCC)
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
This prospective observational study (PKU-ESCC-Monitor) aims to characterize the dynamic evolution of esophageal squamous cell carcinoma (ESCC) using integrated multi-omics, including tissue genomics, ctDNA, imaging features…
- Trial name
- PKU-ESCC (NCT07152535)
- Volunteers
- 255 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Non-small Cell Lung Cancer
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
- Trial name
- NCT03791034
- Where
- South Korea
- Volunteers
- 700 people
- Sponsor
- Samsung Medical Center
Gastric Cancer
Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
This study aims to evaluate the clinical value of circulating tumor DNA (ctDNA) as a minimally invasive biomarker for monitoring treatment response and guiding systemic therapy in patients with gastric or gastroesophageal…
- Trial name
- NCT07517107
- Testing
- Circulating Tumor DNA (ctDNA) Analysis, Standard Systemic Therapy for Gastric Cancer
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fudan University
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant…
- Trial name
- B-STRONGER-I (NCT06230185)
- Where
- 14 sites in United States
- Volunteers
- 422 people
- Sponsor
- Personalis Inc.
Non-Small Cell Lung Cancer
Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection
Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden. In this study, PEAC (Personalized Analysis of Cancer) technology was performed to detect the driver gene mutations from plasma…
- Trial name
- EVOLUTION (NCT04238130)
- Testing
- Perioperative ctDNA Dynamic Monitoring
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Hodgkin Lymphoma
Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial
Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma, ABVD-based upfront treatment in 19 centers in…
- Trial name
- FIL-RougeBIO (NCT05066555)
- Where
- 13 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Colorectal Cancer, Surgery
MRD Application in Colorectal Cancer Patients
We first collect tumor tissue and adjacent tissue to peform the WES sequencing, then collect blood after postoperative surgery 1, 3. 6, 9, 12, 18, 24 month to detect ctDNA.
- Conditions
- Colorectal Cancer, Surgery, Chemotherapy Effect
- Trial name
- NCT06028516
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong First Medical University
Hepatocellular Carcinoma
Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence
HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC.
- Trial name
- NCT05823584
- Where
- Taiwan
- Volunteers
- 207 people
- Sponsor
- TCM Biotech International Corp.
Breast Cancer
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
This trial is a multicenter, open-label, non-comparative, phase II, biomarker-driven adjuvant treatment study involving the periodic collection and analysis of blood samples from patients with HR-positive/HER2-negative…
- Trial name
- MiRaDoR (NCT05708235)
- Testing
- Giredestrant, Abemaciclib, Inavolisib
- Where
- 41 sites in Spain, United Kingdom
- Volunteers
- 976 people
- Sponsor
- MedSIR
Colorectal Cancer
Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence
This observational study aims to assess the predictive value of postoperative circulating tumor DNA (ctDNA) monitoring in evaluating the risk of recurrence in stage I-IV colorectal cancer patients.
- Trial name
- NCT06143644
- Testing
- Serial ctDNA monitoring
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Metastatic, HER2 + Breast Cancer
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment
Anti-HER2 therapy, such as trastuzumab and pertuzumab, has significantly improved long-term survival in HER2-positive breast cancer.
- Trial name
- HER2 CR (NCT06663787)
- Testing
- Trastuzumab (Herceptin), SIgnatera
- Where
- 4 sites in United States, Japan
- Volunteers
- 50 people
- Sponsor
- Nagoya City University
EGF-R Positive Non-Small Cell Lung Cancer
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients.
- Trial name
- NCT06287593
- Testing
- ctDNA monitoring
- Volunteers
- 300 people
- Sponsor
- Zhejiang University
Stage IIIb and IV Non Small Cell Lung Cancer
Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer
The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- ANTiCIPe (NCT02169349)
- Testing
- laboratory biomarker analysis, Next Generation Sequencing, DNA Analysis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Rennes University Hospital
NSCLC
The Dynamic Monitoring of Cerebrospinal Fluid ctDNA
Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis, vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to dynamically monitor ctDNA in cerebrospinal fluid (CSF)…
- Trial name
- NCT06315686
- Testing
- pemetrexed
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Metastatic Breast Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast…
- Trial name
- PADA-1 (NCT03079011)
- Testing
- Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product
- Where
- 82 sites in France
- Volunteers
- 1,017 people
- Sponsor
- UNICANCER
Lung Cancer
MRD Monitoring in Lung Cancer After Resection
The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA…
- Trial name
- NCT04976296
- Testing
- MRD detection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangdong Provincial People's Hospital